Allogene Therapeutics Inc

NASDAQ:ALLO   3:59:53 PM EDT
21.71
-0.34 (-1.54%)
Products

Allogene Therapeutics Granted FDA Fast Track Designation For Allo-605 For The Treatment Of Relapsed/Refractory Multiple Myeloma

Published: 06/30/2021 13:12 GMT
Allogene Therapeutics Inc (ALLO) - Allogene Therapeutics Granted FDA Fast Track Designation for Allo-605, the First Turbocar T Cell Therapy, for the Treatment of Relapsed/refractory Multiple Myeloma.